Quarterly Trends of TB Treatment Outcomes as Xpert MTB/Rif Rolled Out in Manicaland, Zimbabwe for 2017 and 2018
Downloads
Background: The World Health Organization target is to reduce to zero the number of death due to Mycobacterium tuberculosis by the year 2035. The earlier TB treatment is commenced, the less chance of a TB associated death and the higher the chance of successful treatment outcomes.
Objective: The objective of the study was to evaluate quarterly trends of TB treatment outcomes as Xpert MTB/Rif testing services rolled out in Manicaland for 2017 and 2018.The study gave an opportunity for the Zimbabwe National TB Program to generate some evidence showing implementation of the intervention, Xpert MTB/Rif diagnostic test.
Method: In the retrospective study , a total of 3277 TB patient variables were captured from facility TB registers .The population was all TB patients recorded in the 304 health facilities as having received TB treatment between 1 January 2017 and 31 December 2018. The scope of the study did not include capturing the full range of variables that are determinants of TB treatment outcomes.
Results: The study demonstrates that the proportion of TB treatment outcome of died had a steady decrease from quarter one of 2017, which had 30/238 (12.6%) to quarter two 2018 which had 41/431 (9.5%). Then quarter three of 2018 the outcome died had a slight increase to just slightly above 10.0% , before going back to just below 10.0% in quarter four of 2018. The proportion of cured for 2017 first quarter was 90/238(37.8%) and that for 2018 quarter four was 147/313 (47.0%). TB treatment outcome of treatment completed for 2017 quarter one was 91/238(38.2%) then for 2018 quarter one, it was 205/464(44.1%).There was no noticeable trend in the two TB treatment outcomes of cured and treatment completed during the eight evaluated quarters.
Conclusion: Overall the TB treatment outcome of died showed a decreasing trend over the eight quarters. In order to avoid inferring the decrease to Xpert MTB/Rif roll out, more variables that are determinants of TB treatment outcomes have to be analysed in future studies.
World Health Organization. The End TB Strategy. Geneva, Switzerland: WHO, 2015. https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1 Accessed November 2020
Abdullahi O, Moses N, Sanga D, Annie W. The effect of empirical and laboratory-confirmed tuberculosis on treatment outcomes. Sci Rep. 2021 Jul 21;11(1):14854. doi: 10.1038/s41598-021-94153-0. PMID: 34290301; PMCID: PMC8295390.
Zvinoera K, Olaru ID, Khan P, Mutsvangwa J, Denkinger CM, Kampira V, Coutinho D, Mutunzi H, Pepukai M, Chikaka E, Zinyowera S, Mharakurwa S, Kranzer K. The impact of changing the diagnostic algorithm for TB in Manicaland, Zimbabwe. Public Health Action. 2021 Dec 21;11(4):196-201. doi: 10.5588/pha.21.0040. PMID: 34956848; PMCID: PMC8680185.
WHO Definitions and reporting framework for tuberculosis -2013 revision ( updated December 2014 and January 2020)
Snow KJ, Cruz AT, Seddon JA, Ferrand RA, Chiang SS, Hughes JA, Kampmann B, Graham SM, Dodd P J, Houben R M, et al . Adolescent tuberculosis. Lancet Child Adolesc Health. 2020 Jan;4(1):68-79. doi: 10.1016/S2352-4642(19)30337-2. Epub 2019 Nov 18. Erratum in: Lancet Child Adolesc Health. 2019 Nov 27; PMID: 31753806; PMCID: PMC7291359.
Shewade HD, Jeyashree K, Mahajan P, Shah AN, Kirubakaran R, Rao R, Kumar AMV. Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. PLoS One. 2017 Oct 23;12(10):e0186697. doi: 10.1371/journal.pone.0186697. PMID: 29059214; PMCID: PMC5653348.
Mutembo S, Mutanga JN, Musokotwane K, Kanene C, Dobbin K, Yao X, Li C, Marconi V C, Whalen C C,. Urban-rural disparities in treatment outcomes among recurrent TB cases in Southern Province, Zambia. BMC Infect Dis. 2019 Dec 30;19(1):1087. doi: 10.1186/s12879-019-4709-5. PMID: 31888518; PMCID: PMC6938018.
Ogyiri L, Lartey M, Ojewale O, Adjei AA, Kwara A, Adanu RM, Torpey Kl. Effect of HIV infection on TB treatment outcomes and time to mortality in two urban hospitals in Ghana-a retrospective cohort study. Pan Afr Med J. 2019 Apr 26;32:206. doi: 10.11604/pamj.2019.32.206.18673. PMID: 31312318; PMCID: PMC6620068.
Schmidt BM, Geldenhuys H, Tameris M, Luabeya A, Mulenga H, Bunyasi E, Scriba T, Hatherill M. Impact of Xpert MTB/RIF rollout on management of tuberculosis in a South African community. S Afr Med J. 2017 Nov 27;107(12):1078-1081. doi: 10.7196/SAMJ.2017.v107i12.12502.
PMID: 29262960.
Tesema T, Seyoum D, Ejeta E, Tsegaye R(2020) Determinants of tuberculosis treatment outcome under diretly observed treatment short courses in Adam City, Ethiopia, Plos one 15 (4):e0232468. https://doi.org/10.1371/journal.pone.0232468
Katana GG, Ngari M, Maina T, Sanga D, Abdullahi OA. Tuberculosis poor treatment outcomes and its determinants in Kilifi County, Kenya: a retrospective cohort study from 2012 to 2019. Arch Public Health. 2022 Feb 5;80(1):48. doi: 10.1186/s13690-022-00807-4. PMID: 35123570; PMCID: PMC8818215
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347. doi: 10.1371/journal.pmed.1001347. Epub 2012 Nov 20. PMID: 23185139; PMCID: PMC3502465.
Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, Metcalfe J, Mutetwa R . Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial. Open Forum Infect Dis. 2014 Jun 25;1(1):ofu038. doi: 10.1093/ofid/ofu038. PMID: 25734106; PMCID: PMC4324195.
Zimbabwe National Statistics Agency. Census 2012 Report. Harare, Zimbabwe: NSA, 2012. https://unstats.un.org/unsd/demographic-social/census/ documents/Zimbabwe Accessed March 2021.
Sadykova L, Abramavičius S, Maimakov T, Berikova E, Kurakbayev K, Carr NT, Padaiga Z, Naudziunas A, Stankevicius E. A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013-2016. Medicine (Baltimore). 2019 Jun;98(26):e16071.
doi: 10.1097/MD.0000000000016071.
PMID: 31261516; PMCID: PMC6617166.
Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687. PMID: 33653759; PMCID: PMC7929865.
Adejumo OA, Daniel OJ, Adebayo BI, Adejumo EN, Jaiyesimi EO, Akang G, Awe A. Treatment Outcomes of Childhood TB in Lagos, Nigeria. J Trop Pediatr. 2016 Apr;62(2):131-8. doi: 10.1093/tropej/fmv089. Epub 2015 Dec 24. PMID: 26705331; PMCID: PMC4886120.
Sadykova L, Abramavičius S, Maimakov T, Berikova E, Kurakbayev K, Carr NT, Padaiga Ž, Naudžiūnas A, Stankevičius E. A retrospective analysis of treatment outcomes of drug-susceptible TB in Kazakhstan, 2013-2016. Medicine (Baltimore). 2019 Jun;98(26):e16071. doi: 10.1097/MD.0000000000016071. PMID: 31261516; PMCID: PMC6617166.
Dedefo MG, Sirata MT, Ejeta BM, Wakjira GB, Fekadu G, Labata BG. Treatment Outcomes of Tuberculosis Retreatment Case and Its Determinants in West Ethiopia. Open Respir Med J. 2019 Dec 31;13:58-64. doi: 10.2174/1874306401913010058. PMID: 32175031; PMCID: PMC7040470.
Wang CS, Chen HC, Chong IW, Hwang JJ, Huang MS. Predictors for identifying the most infectious pulmonary tuberculosis patient. J Formos Med Assoc. 2008 Jan;107(1):13-20. doi: 10.1016/S0929-6646(08)60003-0. PMID: 18218573.
All Content should be original and unpublished.
